PT - JOURNAL ARTICLE AU - Butler-Laporte, Guillaume AU - Farjoun, Joseph AU - Nakanishi, Tomoko AU - Lu, Tianyuan AU - Abner, Erik AU - Chen, Yiheng AU - Hultström, Michael AU - Metspalu, Andres AU - Milani, Lili AU - Mägi, Reedik AU - Nelis, Mari AU - Hudjashov, Georgi AU - Estonian Biobank Research Team AU - Yoshiji, Satoshi AU - Ilboudo, Yann AU - Liang, Kevin YH AU - Su, Chen-Yang AU - Willet, Julian DS AU - Esko, Tõnu AU - Zhou, Sirui AU - Forgetta, Vincenzo AU - Taliun, Daniel AU - Richards, J Brent TI - HLA allele-calling using whole-exome sequencing identifies 129 novel associations in 11 autoimmune diseases: a multi-ancestry analysis in the UK Biobank AID - 10.1101/2023.01.15.23284570 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.15.23284570 4099 - http://medrxiv.org/content/early/2023/04/21/2023.01.15.23284570.short 4100 - http://medrxiv.org/content/early/2023/04/21/2023.01.15.23284570.full AB - The human leukocyte antigen (HLA) region on chromosome 6 is strongly associated with many immune-mediated and infection-related diseases. Due to its highly polymorphic nature and complex linkage disequilibrium patterns, traditional genetic association studies of single nucleotide polymorphisms (SNPs) do not perform well in this region. Instead, the field has adopted the assessment of the association of HLA alleles (i.e., entire HLA gene haplotypes) with disease. Often based on genotyping arrays, these association studies impute HLA alleles, decreasing accuracy and thus statistical power for rare alleles and in non-European ancestries. Here, we use whole-exome sequencing (WES) from 454,824 UK Biobank participants to directly call HLA alleles using the HLA- HD algorithm. We show this method is more accurate than imputing HLA alleles and harness the improved statistical power to identify 360 associations for 11 auto-immune phenotypes (at least 129 likely novel), leading to better insights into the specific coding polymorphisms that underlie these diseases. We show that HLA alleles with synonymous variants, often overlooked in HLA studies, can significantly influence these phenotypes. Lastly, we show that HLA sequencing may improve polygenic risk scores accuracy across ancestries. These findings allow better characterization of the role of the HLA region in human disease.Competing Interest StatementJBR's institution has received investigator-initiated grant funding from Eli Lilly, GlaxoSmithKline and Biogen for projects unrelated to this research. He is the CEO of 5 Prime Sciences Inc (www.5primesciences.com). JF, TL, and VF are employees of 5 Prime Sciences Inc. TN has received speaking fee from Boehringer Ingelheim for talks unrelated to this research.Funding StatementThe Richards group is supported by the Canadian Institutes of Health Research (CIHR), the Lady Davis Institute of the Jewish General Hospital, the Canadian Foundation for Innovation, the NIH, Cancer Research UK, and FRQS. The Richards research group is supported by the Canadian Institutes of Health Research (CIHR: 365825; 409511, 100558, 169303), the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), the Lady Davis Institute of the Jewish General Hospital, the Jewish General Hospital Foundation, the Canadian Foundation for Innovation, the NIH Foundation, Cancer Research UK, Genome Quebec, the Public Health Agency of Canada, McGill University, Cancer Research UK [grant number C18281/A29019] and the Fonds de Recherche Quebec Sante (FRQS). JBR is supported by an FRQS Merite Clinical Research Scholarship. TwinsUK is funded by the Welcome Trust, Medical Research Council, European Union, the National Institute for Health Research (NIHR)-funded BioResource, Clinical Research Facility and Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust in partnership with King's College London. GBL received a scholarship from the FRQS and the CIHR. These funding agencies had no role in the design, implementation or interpretation of this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All primary data are available through the UK Biobank and the Estonian Biobank.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll code for the UK Biobank analysis is available on https://github.com/DrGBL/HLA_UKB. The primary data used for the UK Biobank analyses (i.e. WES CRAM files) is available through the UK Biobank DNAnexus research analysis platform. The primary data for the Estonian Biobank is available through the Estonian Biobank. All summary statistics can be found in the supplements.